New Immunotherapy Combinations Look to Create Maximum Velocity in Immune Systems Response to Cancer
5 Most Recent FDA Approvals Patients With Cancer May Have Missed
Good News For Rare Cancer Treatment, Keytruda Can Help
The authors of this post hoc analysis of a randomized phase III trial evaluated the impact of treatment adherence to neoadjuvant chemoradiotherapy and/or adjuvant chemotherapy on disease-free survival among 1232 patients with locally advanced rectal cancer. Complete adherence to neoadjuvant chemoradiotherapy compared with reduced adherence was associated with improved 3-year disease-free survival. However, complete versus incomplete adherence to adjuvant chemotherapy was not associated with disease-free survival.
Future trials should be designed to facilitate the delivery of optimal neoadjuvant chemoradiotherapy.
– Paul J. Hampel, MD
Users browsing this forum: boxhill and 5 guests